ALSEN — Sensorion SA Share News
0.000.00%
Last trade - 00:00Europe Research Roundup: Ashmore, Chemring Group, Qinetiq Group
Brief: Sensorion Says CEO Nawal Ouzren To Step Down
Analysis: Trump health policy uncertainty sends biotech sector into deeper slump
Brief: Sensorion Announces EUR 15 Mln Financing, Extending Cash Runway Until End 2025
'Embracing gene therapy era', Stifel starts Sensorion at 'buy'
Brief: Sensorion Expects It Can Finance Operations Until End Q2 2025
Brief: Sensorion Met Primary Endpoint For Sens-401 Phase 2A Clinical Study
Brief: Sensorion: successful completion of EUR 50.5 million financing
Brief: Sensorion Completes Patient Inclusion In Phase 2A Clinical Trial Of SENS-401 For Residual Hearing Preservation
Brief: Sensorion Announces Approval For Lead Gene Therapy Candidate Trial Of SENS-501 (OTOF-GT) In Some European Countries
Brief: Sensorion Partners With Institut Pasteur On Gene Therapy Programs
Brief: Sensorion Provides Update On Notoxis
Europe Research Roundup: Brooks MacDonald Group, TUI, Weir Group
Brief: Sensorion Development Milestone For Sens-501 Program
Brief: French company Sensorion raises 35 mln euros via private placement
Europe Research Roundup: Boliden AB, Fortum Oyj, Schibsted ASA
Brief: Sensorion Submits Clinical Trial Application For OTOF-GT
Brief: Sensorion Submits Clinical UK Trial Application For Lead Gene Therapy Candidate Otof-Gt
Brief: Sensorion Reports Positive Efficacy Data From Sens-401 Phase 2A Clinical Study